Home›The Library›Sargramostim
Sargramostim
Sargramostim (Leukine) is a real, FDA-approved recombinant GM-CSF, first approved in 1991 for bone marrow transplant recovery — and, in 2018, approved for acute radiation syndrome based entirely on animal studies, since human radiation-exposure trials are neither ethical nor feasible.
On this page
In brief
Should you care? Relevant if you or someone you know is undergoing bone marrow transplant, or as a case study in how the FDA approves drugs for scenarios too dangerous to test in humans.The short version
- Recombinant GM-CSF, mechanistically distinct from filgrastim's G-CSF — stimulates a broader range of myeloid cell lineages, not just neutrophils.
- Approved 1991 for bone marrow transplant recovery.
- Approved 2018 for acute radiation syndrome under the FDA's "Animal Rule" — based entirely on nonhuman primate survival data, since deliberately irradiating humans to test a treatment is obviously not possible.
A broader-acting cousin of G-CSF
Sargramostim is recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), produced in yeast. It's mechanistically distinct from filgrastim and pegfilgrastim's G-CSF: GM-CSF acts on a broader range of myeloid progenitor cells, stimulating neutrophils, macrophages, and eosinophils rather than neutrophils specifically.
The 1991 approval
The FDA approved sargramostim (as Leukine) in March 1991 to accelerate white-blood-cell recovery after autologous bone marrow transplantation, with the indication expanded in December 1991 to cover engraftment delay or failure after transplant. Additional hematology-oncology indications, including use around allogeneic transplant and induction chemotherapy for acute myeloid leukemia, followed over subsequent years.
The 2018 approval: evidence from animals only
In 2018, the FDA approved sargramostim for adults and children acutely exposed to myelosuppressive doses of radiation (the hematopoietic subsyndrome of acute radiation syndrome, or H-ARS) — a genuinely notable regulatory case study. The approval used the FDA's "Animal Rule" (21 CFR 314.610), a pathway that allows approval based on adequate and well-controlled animal studies when human efficacy trials are neither ethical nor feasible — nobody can be deliberately exposed to near-lethal radiation to test a treatment. The approval rested on two nonhuman primate studies: one evaluating delayed dosing up to 120 hours post-exposure (Int J Radiat Biol, PMID 32960660), and a second finding improved 60-day survival in severely bone-marrow-suppressed primates after high-dose whole-body irradiation (Radiat Res 2021;195(2):191-199, DOI: 10.1667/RADE-20-00131.1). Sargramostim was the first H-ARS drug shown to improve survival even when started a full 48 hours after exposure.
Current status
Still marketed, currently by Partner Therapeutics. No grey-market or wellness-adjacent presence — a hospital-administered biologic for specific hematologic and radiation-exposure indications.
References
- FDA approval history for Leukine (sargramostim): autologous bone marrow transplant, March 1991; engraftment delay/failure, December 1991.
- Hankey KG, Farese AM, Blaauw EC, et al., "Efficacy of delayed administration of sargramostim up to 120 hours post exposure in a nonhuman primate total body radiation model," Int J Radiat Biol 2021;97(sup1):S127-S136, PMID 32960660.
- Farese AM, Hankey KG, Cohen MV, et al., "Sargramostim (rhu GM-CSF) Improves Survival of Non-Human Primates with Severe Bone Marrow Suppression after Acute, High-Dose, Whole-Body Irradiation," Radiat Res 2021;195(2):191-199, DOI: 10.1667/RADE-20-00131.1.
- FDA approval of Leukine (sargramostim) for hematopoietic subsyndrome of acute radiation syndrome (H-ARS), 2018, under the Animal Rule (21 CFR 314.610).